# Vaccine misinformation: ingredients, cumulative schedules, and natural infection

Research cutoff: 14 October 2026. Prepared for Getting It Right. This is an editorial research dossier, not individualized medical advice or a publication instruction.

## Decision first

1. **Build an ingredient hub, with a substantial, directly linkable formaldehyde section.** Formaldehyde is a documented, recurring ingredient scare with fresh 2025–26 examples. The evidence does not establish it as a leading standalone belief or provide a contemporary population prevalence estimate. Do not describe it as obscure or extinct either. A short supporting page might serve navigation, but a flagship standalone page is a lower priority than the subjects below.
2. **Aluminum is a strong standalone candidate.** It has an unusually developed scientific argument, organized campaigns, recent research and counter-research, and 2026 institutional attention. A page can explain route, chemical form, clearance, the actual local adverse effects, and what large human studies can and cannot establish. Cross-link the existing autism page instead of duplicating it.
3. **“Too many, too soon / spacing is healthier” deserves a standalone explainer.** It has better direct belief measurement than formaldehyde. Separate immune-system overload, cumulative ingredient exposure, and claims that an entire schedule was never studied. Those are different propositions.
4. **Keep a substantial thimerosal section, with an optional standalone policy explainer.** It remains actively revived, and a Canadian survey directly measures a mercury–autism belief. U.S. recommendations, an FDA-approved formulation, actual supply, and worldwide use are different facts. Historical recommendation text cannot establish the operative policy without checking subsequent litigation.
5. **Natural infection as a preferable route to immunity merits disease-specific treatment or a standalone parent page.** The valid observation that infection can produce immunity does not establish that contracting the disease is a safer or generally healthier strategy. Recent measles rhetoric makes this an active issue.
6. **Ingredient-list disgust, fetal/animal-cell rhetoric, and “vaccinated versus unvaccinated” chronic-disease studies belong in the hub/schedule architecture initially.** Monitor specific large waves rather than creating a page for every ingredient or new preprint.

These are editorial priorities, not a computed popularity league table. The records below distinguish current activity, historical persistence, belief measurement, and unmeasured reach.

## 1. Narrative matrix

| Family and variants | Verified geography; language separately | Activity and prominence assessment | Likely decision harm | Technique and why it fits | Correct counterclaim and limits | Editorial disposition |
|---|---|---|---|---|---|---|
| **Formaldehyde means poisoning/cancer**: embalming fluid; salon formalin; leukemia; “any carcinogen is unsafe”; bundled chemical lists | Brazil: Portuguese regulator observed a fresh flu wave in March 2026. Germany: German author, January 2025. U.S.-origin material also published in Spanish. UNICEF monitoring lists eight countries; translations include French, Spanish and Portuguese, without establishing country-specific prevalence. | **Persistent and currently recurring**, usually bundled with other ingredients. Strong evidence it exists; weak evidence of standalone scale. Sources D1–D5. No representative formaldehyde-specific belief item found. | Refusal of otherwise indicated vaccines; mistaken rejection of products that do not contain it; distrust based on occupational-hazard imagery. These are plausible pathways, not measured formaldehyde-attributable casualties. | Hazard–risk conflation: a substance’s ability to cause harm at some exposure is substituted for risk at the actual dose/route. Guilt by association: embalming/salon use substitutes for exposure analysis. | Some products contain small residual amounts; some do not. Evaluate the exact formulation, injected dose, metabolism and evidence. Endogenous occurrence is context, not a proof of safety. F1–F4 and product table. | Ingredient-hub anchor now. Standalone only if independently demonstrated audience demand or a large, well-measured new wave justifies it. |
| **Aluminum causes brain injury, autism, autoimmunity or systemic macrophagic myofasciitis (MMF)**; “FDA limit exceeded”; “accumulates forever” | U.S.: English CHD advocacy and government attention in 2026. Canada: English CHD chapter republication. France: French E3M campaign. Spanish-language reprints exist; publisher location is not assumed. | **Active, organized and institutionally amplified**. No comparable current population aluminum-belief estimate located, so activity is not prevalence. D6–D10. | Broad refusal/delay; inappropriate “detox” responses; failure to distinguish real local reactions from unsupported systemic causal claims. | Dose/route conflation when an intravenous nutrition warning is treated as an intramuscular vaccine threshold; mechanistic speculation presented as established clinical causation; selective emphasis on a positive signal while omitting later evidence. | Aluminum salts act as adjuvants in some products. Current human evidence does not support the asserted broad serious/long-term causal harms. Persistent itchy nodules and hypersensitivity are real and should be acknowledged. The 2022 asthma association and later non-replication must both be shown. A1–A5. | Strong standalone candidate, linked to hub and existing autism page. |
| **Thimerosal/mercury poisoning and autism**; removal proves past harm; all childhood vaccines contain mercury | U.S.: English ACIP presentation and policy debate in 2025, international funding statement in July 2026. Canada: English/French survey fielded November 2024. Brazil: Portuguese flu rumors in 2026. | **Persistent, actively revived, with direct belief evidence**, although the Canadian item is mercury–autism and the fieldwork predates its 2025 report. P3, D2, D11–D13. | Refusal of flu or multidose vaccines, including settings where alternative supply differs; false extrapolation to every product. | Chemical-form conflation between methylmercury and ethylmercury; precaution/policy-change-as-confession; country/formulation conflation. | Thimerosal is a preservative in certain multidose presentations. Its ethylmercury pharmacokinetics differ from methylmercury. Current evidence does not support autism causation. Neither faster clearance nor a policy change alone proves all safety questions. T1–T4. | Substantial hub section; consider standalone if international flu/policy coverage is central. Autism content should update the existing page. |
| **Too many/too soon/overload; separate shots or visits are healthier; schedules untested** | U.S.: English/Spanish probability-panel parent survey, July–August 2025; English executive order August 2026. Historical EU28 survey in respondents’ native languages. Canada: bilingual 2022 parent survey. | **High editorial priority**: directly measured spacing preference plus current institutional attention. Different surveys ask different things and cannot be pooled. P1, P4–P5, D10. | Undervaccination and longer susceptible intervals; extra visits can also create missed opportunities. Not every short delay has the same demonstrated risk. | Intuitive finite-capacity analogy; counting injections or named diseases as though that measures immune burden; treating lack of one all-purpose trial as absence of all safety evidence. | Evaluate the specific schedule/product combination and outcome. Relevant cumulative-exposure studies exist, but no single study proves every combination harmless. Recommended-dose deficits have measurable disease risks; “every delay multiplies risk” overstates the evidence. S1–S3. | Standalone explainer; include cumulative chemical exposure as a separate subsection linked to aluminum. |
| **Unvaccinated children are generally healthier; vaccines explain rising chronic disease** | U.S.: September 2026 CHD article and U.S.-practice preprint; English. | **Active latest variant**, not yet a measured population effect of this particular preprint. The study and its promotional article are not independent confirmations. D14. | Global refusal based on associations that may reflect ascertainment, healthcare use and selection. | Correlation-to-causation; “any vaccination” silently becomes the complete recommended schedule; diagnostic coding becomes biological incidence; one selected dataset becomes universal. | Appraise denominators, timing, healthcare encounters, covariates and comparator selection. A crude comparison cannot isolate an ingredient or establish a causal effect of the full schedule. This is a methodological criticism, not a claim that every vaccinated/unvaccinated design is invalid. | Schedule/testing section, with a dated case study; watch for broader independent uptake. |
| **Natural infection is superior, strengthens children generally, prevents later cancer/heart disease** | U.S.: English McCullough publication March 2025; CHD measles article September 2026. COVID-specific versions are a separate subject. | **Persistent and active**; recent direct publication establishes dissemination, not unique reach or national endorsement. D15–D16. | Deliberate infection or refusal; underestimation of complications and transmission to vulnerable people. | Naturalistic fallacy when “natural” substitutes for net benefit; survivor bias; selective immunogenicity endpoints or observational correlations substitute for the total risk of acquiring infection. | Infection can confer immunity, sometimes durable. That benefit comes after exposure to disease risks; measles can also erase parts of prior immune memory. Compare particular diseases, vaccines, populations and outcomes; do not assert that vaccine immunity is always stronger or longer. S4–S5. | Standalone parent explainer or disease-specific pages; prioritize measles, link rather than duplicate COVID work. |
| **Dirty/unnatural ingredients: animal organs, fetal cells, antifreeze, detergents** | U.S.: English CHD physician questionnaire, currently accessible but publication date unverified. Portuguese Brazilian flu wave includes octoxynol-10. U.S. historical probability-panel ingredient question. | **Persistent broad family** with measured historical belief and current bundled examples. The undated questionnaire is not evidence of a 2026 surge. P2, D2, D5. | Rejection based on misleading descriptions of manufacture and final contents; ethical concerns can be obscured by factual disputes. | Disgust framing and category errors: production cell substrates, processing agents, residuals and final ingredients are collapsed into one list. A frightening use of a chemical is substituted for its function and exposure. | Explain the exact production process and label, without pretending cell lines or animal-derived materials never exist. Ethical/religious objections are not themselves factual misinformation. Do not label every allergy concern false. | Ingredient-hub section; short linked answers only for demonstrated demand. |

## 2. What prominence evidence actually shows

### P1. U.S. schedule/spacing belief, not ingredient-specific fear

[KFF/Washington Post survey and methods](https://www.kff.org/public-opinion/kff-the-washington-post-survey-of-parents/); [original questionnaire/topline](https://files.kff.org/attachment/topline-kff-washington-post-survey-of-parents.pdf), Q16, Q44, Q46.

Published 10 October 2025; fieldwork 18 July–4 August 2025. Probability-based Ipsos KnowledgePanel online survey of 2,716 U.S. parents/guardians with under-18s in their household; 2,519 English and 197 Spanish interviews; weighted overall margin ±2 percentage points. Q44 forced a choice between two views, with order rotated: 41% favored the healthier-with-spacing/multiple-shot-avoidance proposition; 57% chose lack of strong evidence for that benefit; 3% skipped (rounding). Separately, 26% thought CDC recommended too many vaccines. Q46b, true/false/insufficient-knowledge, found 13% accepting an increase in vaccines as a likely explanation for rising chronic disease, 45% rejecting, 41% unsure, 1% skipped. Do not convert the “too many” response into a particular overload belief, or the spacing response into formaldehyde concern.

### P2. U.S. broad ingredient myth, historical baseline

[Annenberg original report](https://www.annenbergpublicpolicycenter.org/vaccine-confidence-falls-as-belief-in-health-misinformation-grows/); [wave-13 topline](https://www.annenbergpublicpolicycenter.org/wp-content/uploads/APPC_ASAPH_Toplines_W13.pdf), Q19, PDF page 3.

Fieldwork 5–12 October 2023; 1,559 U.S. adults in the longitudinal SSRS panel; reported margin ±3.4 points. The tested item was “Vaccines in general are full of toxins and harmful ingredients like ‘antifreeze.’” Twelve percent called it true and 73% false. This supports an ingredient-family baseline, not 2026 prevalence, formaldehyde prevalence, or a claim that all ingredient concerns are mistaken.

### P3. Canada: direct mercury–autism measure

[Canadian Medical Association/Abacus 2025 report](https://digitallibrary.cma.ca/media/Digital_Library_PDF/2025%20Health%20and%20media%20annual%20tracking%20survey%20EN.pdf), methods page 2, item page 9.

Actual fieldwork: 12–19 November 2024. Online English/French survey of 3,727 Canadians, including Gen-Z and French oversamples, census weighted. For “Mercury in vaccines can cause autism,” 26% selected definitely/probably true and 28% were unsure. The PDF's ±1.96 comparison is for a hypothetical probability sample of this size; it does not establish that this online sample has probability-sampling error. Retain that limitation. This is a Canadian estimate under this instrument, not a global percentage or formaldehyde finding.

### P4. Canada: concern reasons have a restricted denominator

[Health Canada/EKOS childhood-vaccination attitudes report](https://epe.lac-bac.gc.ca/100/200/301/pwgsc-tpsgc/por-ef/health/2023/030-22-e/030-22-Report.html?nodisclaimer=1).

October 2022 fieldwork, published February 2023; n=1,228, comprising 1,035 parents of children 0–6 and 193 pregnant/planning respondents. Probability-recruited Probit panel, predominantly online with about 15% telephone; bilingual interviewing. Overall margin ±2.80 points, larger for subgroups. Among **604 respondents with some/many concerns or who refused some/all vaccines**, a select-all main-reasons question yielded 8% toxic ingredients, 17% too many in a short period, 12% too many required, and 7% belief the body can handle illness. Those are not percentages of all Canadians or all parents. Wording changes limit comparison with earlier waves.

### P5. Historical EU28 immune-overload measure

[European Commission original Special Eurobarometer 488](https://health.ec.europa.eu/system/files/2019-04/20190426_special-eurobarometer-sp488_en_0.pdf), QC7.1 and technical appendix.

15–29 March 2019; 27,524 respondents aged 15+, multistage probability sampling, face-to-face home interviews in native languages across the then EU28. The proposition “Vaccines overload and weaken the immune system” received 31% true, 55% false and 14% don't know. This is a useful historical cross-country baseline, not a current European prevalence claim. Geography is EU28 at that time, including the UK; a multilingual instrument is not evidence all countries have the same prevalence.

### Additional evidence deliberately kept out of rankings

- [U.S. September 2022 primary survey study](https://pmc.ncbi.nlm.nih.gov/articles/PMC10748314/): probability-based KnowledgePanel, 2,561 eligible adults including 767 parents, English/Spanish fieldwork 1–12 September. Ingredient concern was reported by 47% of adults and 52% of parents, but concern is not assent to a false claim. Its natural-immunity item was COVID-specific, so it cannot establish measles beliefs.
- [Arif et al., 2018, original multilingual search study](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.01215/full), Table 7: June–September 2017 localized searches on vaccine/autism terms in six languages. Of 225 vaccine-negative pages, six mentioned formaldehyde, 57 aluminum and 81 thimerosal. This is an old, query-conditioned web-content sample, not today's online share, reach, or public belief. It offers only historical context for treating formaldehyde as one ingredient among others.
- A [Brazilian study published in 2025](https://pubmed.ncbi.nlm.nih.gov/39579518/) reports responses about natural immunity in 4,305 participants, but without fully verified recruitment and field dates it should not be presented here as a national probability estimate. “Failed to disagree” also must not be silently renamed firm belief.

## 3. Dated dissemination and activity ledger

Primary publications below demonstrate what an organization/author actually circulated. They are **not medical authorities merely because they are primary evidence of dissemination**. Monitoring reports establish observed circulation; they do not prove that every reader believed the content.

### Bundled ingredients and formaldehyde

**D1. 8 September 2025, UNICEF-managed Polio Pulse.** [Original monitoring report](https://poliokit.org/index.php/pulse/aluminum-formaldehyde-online-crusade-against-poisoned-polio-drops). Describes an ingredient-toxicity wave across X, YouTube, translated memes and Brazilian Telegram recirculation, bundling aluminum, formaldehyde, mercury and thimerosal with cancer, neurological harm and sterility. Listed countries: U.S., UK, France, Japan, India, Nigeria, Brazil and Germany. Reported translations include French, Spanish and Portuguese. Its “medium risk” classification is a monitoring judgment. No unique-reach denominator, population belief measure or ingredient-separated engagement total was supplied. Direct page access was intermittently unreliable; the original report was also independently recovered by the parallel prominence audit. The campaign's “polio drops” framing makes the oral-versus-injectable distinction especially important.

**D2. 30 March 2026, updated 1 July, Brazil.** [Anvisa original response](https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-reforca-seguranca-da-vacina-contra-gripe-e-desmente-boatos-sobre-componentes-1/). The regulator describes a fresh misinformation wave around the 28 March flu campaign, involving thimerosal, octoxynol-10 and formaldehyde/formol. The reported claims connect ingredients to neurological/kidney harm, autoimmune disease, cancer and leukemia. This confirms a Portuguese-language, Brazil-specific recurrence, without a reach estimate. Its own broad concentration comparisons and categorical carcinogenicity wording should not be copied without qualification; use product labels and route-specific toxicology instead.

**D3. 7 January 2025, Germany/German.** [Elke Austenat original article](https://elkeaustenat.de/2025/01/07/ein-heisses-eisen-impfungen-und-autismus-spektrum-stoerungen/) combines aluminum, thimerosal and formaldehyde in an autism/brain-injury argument. This is a dated individual publication with unknown reach, not evidence of national dominance.

**D4. 24 July 2023, Spanish-language U.S.-subject publication.** [CHD's anthrax-vaccine article](https://childrenshealthdefense.org/defender/que-contiene-la-nueva-vacuna-contra-el-antrax-aluminio-formaldehido-y-cloruro-de-bencetonio/?lang=es) foregrounds aluminum, formaldehyde and benzethonium chloride. It demonstrates a persistent ingredient-list framing. Spanish publication does not establish a Spanish national audience, and a 2023 article is not fresh 2026 activity.

**D5. Currently accessible, date unverified.** [CHD pediatrician-questionnaire pack](https://childrenshealthdefense.org/wp-content/uploads/all-questionnaires-pack.pdf) lists formaldehyde/leukemia, aluminum, mercury, animal materials and fetal-cell rhetoric in questions for parents. Useful as a primary example of bundled persuasion, but do not assign an upload date from a search engine or infer a current surge. Ethical concerns require separate, respectful factual explanation.

**Additional observed cross-language wave, May–June 2025.** [AFP's 10 June original investigation](https://factcheck.afp.com/doc.afp.com.493E8T2) documents Jeff Barke's Vaxelis video, a 19 May Canadian Instagram repost, and French, German, Spanish and Croatian versions. [AFP Croatian investigation, 12 June](https://provjeracinjenica.afp.com/doc.afp.com.49XH9ZP) records posts from 5 May with more than 70 shares and 3,000 views as observed at publication. Those are post-level historical counters, not unique people, countrywide belief, or ingredient-specific reach. The video bundles formulation, placebo, cancer-testing and “new vaccine” allegations, so its circulation cannot be attributed to formaldehyde alone. AFP links archived original posts; the original publisher questionnaire and articles above provide additional directly accessible dissemination evidence.

### Aluminum and schedules

**D6. 26 August 2026, U.S./English.** [CHD original retraction-demand article](https://childrenshealthdefense.org/defender/danish-study-claim-aluminum-vaccines-safe-chd-scientists-call-for-retraction/) attacks the Danish cohort and treats corrected supplementary data as supporting harm. This is current organized advocacy, not merely an old myth list. A correction is neither automatically trivial nor evidence of the opposite causal conclusion; inspect what changed.

**D7. 7 February 2026, Canada/English.** [CHD Canada original republication](https://childrenshealthdefense.ca/news/scientists-publish-new-map-alleging-how-aluminum-in-vaccines-can-trigger-brain-injury/) promotes a proposed mechanistic chain from aluminum to brain injury. [Spanish-language publication, 2 February 2026](https://cienciaysaludnatural.com/aluminio-en-vacunas-puede-causar-autismo/) illustrates related recirculation. Publisher geography for the latter was not established. Repetition of the same analysis is not independent scientific replication.

**D8. France/French, sustained 2025–26.** E3M's [press archive](https://www.vaccinssansaluminium.org/espace-presse/) includes 21 April and 24 July 2026 activity; its [response to Milan editions](https://www.vaccinssansaluminium.org/editions-milan-erreurs/) discusses the 2026 BMJ review. This supports an active, organized French aluminum/MMF campaign, without a quantified audience. Acknowledging patients' symptoms does not establish the proposed vaccine cause.

**D9. August 2026 counter-research.** [Primary reanalysis record](https://pmc.ncbi.nlm.nih.gov/articles/PMC13567156/) by Jablonowski and Hooker is part of the dispute over the Danish study. It analyzes published supplementary tables and subgroup results, not newly obtained individual-level Danish records. Full-page access was intermittently blocked by browser verification. Do not describe it as independently validated, retract the Danish result by implication, or pretend the argument has not been made. Publication-level critique should distinguish model choices, available aggregate versus individual data, multiple comparisons and the exact correction. This dossier does not purport to rerun either analysis.

**D10. 10 August 2026, U.S. institutional attention.** [White House executive order](https://www.whitehouse.gov/presidential-actions/2026/08/delivering-gold-standard-childhood-vaccine-recommendations-for-americans/) directs work on alternative adjuvants and separate immunization visits, with provisions about single-disease MMR products when domestically available. This makes the subjects consequential and highly visible at a policy level. The order alone does not prove ingredient harm, that every direction has taken effect, or the present legal status of a recommendation; it itself references litigation. Avoid using it as a prevalence statistic or scientific adjudication.

### Thimerosal and international policy

**D11. 25–26 June 2025, U.S./English.** [Official ACIP minutes](https://www.cdc.gov/acip/downloads/minutes/summary-2025-06-25-26-508.pdf) document Lyn Redwood's thimerosal presentation. [The ensuing MMWR recommendation](https://www.cdc.gov/mmwr/volumes/74/wr/mm7432a2.htm) records a preference for thimerosal-free seasonal flu vaccination and states that GRADE/EtR were not used for that recommendation and the influenza work group had not discussed it. This is unusually direct evidence of institutional amplification; it should not be turned into evidence that thimerosal was newly demonstrated unsafe. **Subsequent legal qualification:** the [16 March 2026 district-court order](https://litigationtracker.law.georgetown.edu/wp-content/uploads/2025/07/American-Academy-of-Pediatrics_2026.03.16_ORDER-ON-MOTION-FOR-PRELIMINARY-INJUNCTION.pdf), pages 44–45, stayed all votes taken by the reconstituted ACIP, encompassing the June 2025 vote. The recommendation is therefore reported here as a dated action and dissemination event, not an unqualified statement of currently operative policy.

**D12. 29 July 2026, international funding context.** [HHS joint statement](https://www.hhs.gov/press-room/joint-statement-strengthening-vaccine-safety-accountability-american-leadership-global-health.html) links U.S. support for Gavi with transitions involving mercury-containing formulations and newer products. Its framing is an active policy channel for the concern. [Gavi's 30 July statement](https://www.gavi.org/news/media-room/gavi-welcomes-usg-commitment-unlock-funding-fiscal-years-2025-and-2026) welcomes the intended funding release; it does not itself establish every asserted safety premise or that all transitions are complete. Do not generalize U.S. availability to all supported countries.

**D13. Brazil context.** [Ministry of Health FAQ, 5 November 2025](https://www.gov.br/saude/pt-br/composicao/svsa/pni/faq/faq/vacinas/as-vacinas-contem-mercurio-isso) discusses thimerosal in multidose vaccines. Combined with D2, it shows why an answer limited to U.S. childhood products would be incomplete for a Portuguese-speaking global audience.

### Latest chronic-disease and natural-infection variants

**D14. 26–29 September 2026, U.S./English.** [Original CHD-funded preprint on Zenodo](https://zenodo.org/records/22978737), posted 26 September, and [CHD promotion, 29 September](https://childrenshealthdefense.org/defender/vaccinated-kids-significantly-higher-risk-multiple-chronic-health-conditions-chd-study/). The dataset contains 6,239 children in eight U.S. practices, including 3,825 classified unvaccinated. Comparisons use any vaccination before 13 months versus no vaccine ever, diagnoses from encounters at ages 2–4, and largely crude/sex-stratified associations. This is not a randomized full-schedule comparison, and it does not isolate any ingredient. Differences in practice selection, visits and coding can affect recorded diagnoses; temporal ordering and confounding need explicit assessment. The promotion does not establish unique reach or causal harm.

**D15. 5 March 2025, U.S./English.** [Peter McCullough original article](https://www.thefocalpoints.com/p/measles-natural-immunity-superior) presents natural measles immunity as superior. The publicly visible headline and introductory material establish the claim's publication; inaccessible paid text was not bypassed. Unlabeled page counters should not be reported as verified readership.

**D16. 10 September 2026, U.S./English.** [CHD original measles article](https://childrenshealthdefense.org/defender/exclusive-most-kids-fight-measles-naturally-having-virus-may-make-them-stronger/) argues that overcoming measles may strengthen children and discusses later-life benefits. This is an active, recent primary dissemination example with unknown audience. Epidemiological associations or antibody comparisons do not by themselves settle the net risk of intentionally acquiring measles.

**D17. 22 September 2026, cross-cutting U.S./English example.** [CHD original routine-vaccine risk article](https://childrenshealthdefense.org/defender/are-routine-childhood-vaccines-deadlier-than-diseases-they-target/) bundles allegedly missing cumulative-schedule research, vaccinated/unvaccinated comparisons, low present-day disease incidence, pre-vaccine mortality declines, label sections, VAERS-style harm claims and natural immunity. This is useful evidence that the families interlock in a current publication; it supplies no independent reach measurement. A useful editorial response should disentangle incidence from case severity, mortality from incidence, and current low exposure under a vaccination program from a counterfactual without that program. Specific adverse-event claims need their own denominators and causal evidence.

## 4. Formulation audit: amounts are product-specific

Amounts below are **per stated administered volume**, not per vial unless expressly noted. Micrograms (µg) and milligrams (mg) differ by 1,000. Upper residual limits are not measured concentrations for every lot. “Not listed” describes the cited label, not an independent chemical assay or a guarantee about all vaccines sold under a broad disease name.

| Product and primary label | Route/volume | Relevant amount or absence | Editorial importance |
|---|---|---|---|
| [INFANRIX, FDA label](https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm124514.pdf) | Intramuscular, 0.5 mL | Aluminum 0.5 mg; residual formaldehyde ≤100 µg; preservative-free. | One DTaP formulation, not all DTaP or every childhood vaccine. |
| [VAXELIS, FDA label](https://www.fda.gov/media/119465/download), also [DailyMed](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3ed8472a-c6eb-4076-9d66-025ede589e3d&type=display) | Intramuscular, 0.5 mL | Aluminum 319 µg; formaldehyde ≤14 µg; no preservatives. Other manufacturing residuals have separate limits. | A six-disease combination does not mean six times a single-product amount. |
| [RECOMBIVAX HB, DailyMed label](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b5bd99e4-569d-48d5-ba75-16e69f8c409a) | Pediatric intramuscular dose, 0.5 mL | Aluminum 0.25 mg; formaldehyde <7.5 µg in that dose, calculated from label <15 µg/mL; preservative-free. | Do not accidentally quote the per-mL concentration as the pediatric per-dose amount. |
| [IPOL, FDA label](https://www.fda.gov/media/75695/download) | Intramuscular or subcutaneous, 0.5 mL | Formaldehyde maximum 0.02%; 2-phenoxyethanol 0.5%; no aluminum listed. | Injectable inactivated polio product; it cannot stand in for oral polio drops. |
| [GARDASIL 9, FDA label](https://www.fda.gov/media/90064/download) | Intramuscular, 0.5 mL | Approximately 500 µg aluminum as AAHS; no preservative or antibiotics; formaldehyde not listed. | Ingredient profiles differ even among aluminum-adjuvanted vaccines. |
| [M-M-R II, FDA label](https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM123789.pdf) | Intramuscular or subcutaneous, 0.5 mL | Live attenuated viruses; no preservative; aluminum, thimerosal and formaldehyde not listed. Label describes chick-embryo culture and WI-38 human diploid cells, plus residual components. | An autism discussion cannot simply transfer an aluminum argument onto this MMR formulation. Manufacturing-cell questions should be answered accurately. |
| [FLUZONE 2026–27, FDA label](https://www.fda.gov/media/170019/download?attachment=) | Intramuscular, volume/presentation dependent | Single-dose prefilled 0.5 mL: no thimerosal or other preservative. Multidose presentation: 25 µg mercury per 0.5 mL, 12.5 µg per 0.25 mL. | This current approved label still includes a multidose formulation. Approval, recommendation and actual supply are separate; “all flu vaccines” is wrong in either direction. |
| [WHO-prequalified GSK bivalent OPV summary](https://extranet.who.int/prequal/sites/default/files/sf_files/sf_finishedvaccineproducts/VPSAR%20%28Vaccine%20Public%20Summary%20Assessment%20Report%29-pq_184_185_bOPV_GSK_VPASR_Jun16.pdf) | Oral, 0.1 mL/two drops | Live Sabin types 1 and 3; listed excipients include magnesium chloride, arginine and polysorbate 80; aluminum, thimerosal and formaldehyde are not listed. | Concrete counterexample to transferring an injectable-vaccine ingredient list onto “polio drops.” Do not generalize this manufacturer-specific summary to every OPV. |

## 5. Correcting formaldehyde without introducing a new error

### F1. What it does

[FDA's ingredient explainer](https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/common-ingredients-fda-approved-vaccines) describes formaldehyde used in manufacturing certain vaccines to inactivate viruses or detoxify toxins, with small residual quantities in some final products. It also explains endogenous production. Neither “used in manufacture” nor “present in nature” settles the toxicological question. Known carcinogenic hazards from other exposure circumstances must not be denied or simply transferred to an occasional small vaccine injection.

### F2. The relevant injected-dose model

[Mitkus, Hess and Schwartz, Vaccine 2013](https://pubmed.ncbi.nlm.nih.gov/23583892/), DOI 10.1016/j.vaccine.2013.03.071, is an original physiologically based pharmacokinetic assessment. It modeled a 200 µg intramuscular dose in a two-month-old infant; injection-site formaldehyde was modeled as essentially removed within 30 minutes. Under its stated local-metabolism assumptions, estimated peak body-water/blood concentration was 22 µg/L and total amount 66 µg, below 1% of endogenous levels. This specifically addresses an injected exposure rather than relying on food analogy. It remains a model with assumptions, not a trial measuring every possible rare outcome.

### F3. Apples: the natural occurrence is supported, but “higher concentration than vaccines” is not a general fact

The [Hong Kong Centre for Food Safety's official table](https://www.cfs.gov.hk/english/whatsnew/whatsnew_fa/files/formaldehyde.pdf) gives an apple range of **6.3–22.3 mg/kg**. Its [context article](https://www.cfs.gov.hk/english/multimedia/multimedia_pub/multimedia_pub_fsf_06_01.html?hc_location=ufi) notes the limited underlying food-level literature. It is a compiled range, not a precise value for every apple.

**Illustrative arithmetic, not a measured serving:** a 150 g apple at that range contains about 0.945–3.345 mg total formaldehyde. That can exceed the total amount in a vaccine dose. It does **not** prove a higher concentration, and it does not equate swallowing an apple with an intramuscular injection.

For comparison, the INFANRIX label ceiling of 100 µg in 0.5 mL is 200 mg/L; VAXELIS's ceiling is 28 mg/L; RECOMBIVAX HB specifies <15 µg/mL, or <15 mg/L. These are labeled upper limits, not typical batch measurements. Apple mg/kg and vaccine mg/L also use different denominator units and matrices. A universal apples-have-a-higher-concentration claim is unsupported and can be false for a particular comparison. Avoid it.

### F4. Suggested factual wording

“Some vaccines contain a small amount of formaldehyde left over from manufacturing. Whether an exposure is harmful depends on the dose, route, timing and how the body handles it. Assessments of the amounts used in vaccines, including injected-dose modeling, support the safety of those residual amounts.”

Optional context: “Your body also produces and processes formaldehyde.” Add immediately that natural occurrence alone does not make a substance safe. Do not turn “the dose matters” into “only the dose matters”; chemical form, route, duration, vulnerable populations and endpoint matter too.

## 6. Aluminum: strongest current evidence and honest limits

**A1. Current human-evidence synthesis.** [Doyon-Plourde et al., BMJ 2026;393:e088921](https://www.bmj.com/content/393/bmj-2025-088921); [PubMed record](https://pubmed.ncbi.nlm.nih.gov/42091164/). Published 6 May 2026; searches through 27 November 2025. The review included 59 studies: 37 case series, 11 randomized trials, nine cohorts and two ecological studies. The stronger evidence did not support serious or long-term causal outcomes attributed to aluminum-adjuvanted vaccines. Uncommon persistent nodules/granulomas and local hypersensitivity were supported; they can cause prolonged discomfort. Small, biased MMF reports do not establish a systemic clinical syndrome caused by vaccination. Rare/delayed outcomes and uneven evidence quality remain limitations. Do not translate this into “aluminum cannot cause any adverse effect” or “all conceivable outcomes were studied.”

**A2. Large Danish cohort.** [Andersson et al., Annals of Internal Medicine 2025](https://pubmed.ncbi.nlm.nih.gov/40658954/), DOI 10.7326/ANNALS-25-00997. The nationwide cohort included 1,224,176 children and related cumulative vaccine aluminum before age two to 50 chronic outcomes. It did not find increased rates across the outcome groups studied. It is observational, depends on exposure and outcome measurement and cannot exclude every small effect on rare outcomes. Lower estimated rates should not be marketed as aluminum preventing autism. The corrected supplement and subsequent criticism warrant accurate description, not an assumption that correction proves fraud or reverses the conclusion.

**A3. Do not erase the asthma signal.** [Daley et al., original U.S. VSD cohort](https://pubmed.ncbi.nlm.nih.gov/36180331/), online 2022, examined 326,991 children and found associations between cumulative aluminum before 24 months and persistent asthma at 24–59 months, with adjusted hazard ratios per additional milligram of 1.26 among children with eczema and 1.19 among those without. The authors emphasized residual confounding and further investigation. The subsequent Danish study did not replicate an increased asthma association. “No study ever found an association” would therefore be false; an association in one observational study is also not proof of causation.

**A4. Route and kinetics.** [Mitkus et al., Vaccine 2011](https://pubmed.ncbi.nlm.nih.gov/22001122/), DOI 10.1016/j.vaccine.2011.09.124, modeled infant aluminum body burdens incorporating oral absorption, release from injection sites, baseline exposure, growth and renal maturation. It supports safety assessment; it should not be treated as a direct experimental test of every 2026 schedule. A raw mass comparison with diet is inadequate because oral absorption and intramuscular release differ.

**A5. The intravenous-limit trap.** [21 CFR 201.323](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-G/section-201.323) concerns aluminum in parenteral-nutrition products and warns about accumulation with impaired renal function, particularly premature neonates. Its 4–5 µg/kg/day language is not an established maximum safe single intramuscular vaccine dose. The correct response is to explain different exposure circumstances, rather than treating a regulation's existence as irrelevant or asserting that kidneys make any dose harmless.

## 7. Thimerosal: chemistry, labels and policy must stay separate

**T1. Compound versus element.** [FDA thimerosal explainer](https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/thimerosal-and-vaccines) distinguishes ethylmercury from methylmercury. Thimerosal is approximately half mercury by weight: 50 µg compound corresponds to roughly 25 µg mercury, not 50 µg mercury. Chemical form matters. Fish-mercury comparisons alone do not establish vaccine safety.

**T2. Original infant pharmacokinetics.** [Pichichero et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19560158/); [full article](https://pmc.ncbi.nlm.nih.gov/articles/PMC2767297/). In 72 premature newborns of at least 32 and under 37 weeks and 2–3 kg, blood/stool/urine measurements after thimerosal-containing vaccination supported a blood half-life of approximately 6.3 days (95% CI 3.85–8.77), with blood levels back to baseline by 30 days. Blood clearance is useful exposure evidence; it is not, by itself, proof about every tissue or developmental endpoint.

**T3. Current autism evidence.** [WHO GACVS statement, 11 December 2025](https://www.who.int/news/item/11-12-2025-statement-gacvs-vaccines-autism) evaluates updated vaccine/autism evidence, including thimerosal and aluminum. The review supports no causal relationship and distinguishes higher-quality evidence from studies with serious methodological problems. This is material enough to update an existing autism page's evidence date and ingredient links, not to create another autism page. Prefer the review's actual study scope over slogans such as “every vaccine has been proven incapable of causing autism.”

**T4. Current-status warning.** FDA's generic thimerosal page contains older ACIP preference wording. The 2025 policy change and the March 2026 stay in D11 mean that neither webpage chronology nor that sentence alone establishes the currently operative recommendation. Separately, the 2026–27 FLUZONE approved label still lists a multidose formulation with thimerosal. A recommendation is not a chemical assay, an approval is not proof of local supply, and a transition announcement is not proof every country has already switched. [CDC's September 2026 thimerosal explainer](https://www.cdc.gov/flu/vaccine-safety/thimerosal.html) also discusses multidose presentations. Reverify exact local recommendations and legal status before publication; do not use this research as individualized vaccine-selection advice.

## 8. Schedule and natural immunity: evidence proportional to the claim

**S1. Cumulative antigen exposure has been studied.** [Glanz et al., JAMA 2018](https://pmc.ncbi.nlm.nih.gov/articles/PMC5885913/), DOI 10.1001/jama.2018.0708, compared 193 confirmed emergency/inpatient non-vaccine-targeted infection cases with 751 matched controls from a large VSD cohort. Estimated vaccine-antigen exposure through 23 months was not associated with those infections at 24–47 months. This directly informs a particular immune-overload prediction. It is not an all-outcome experiment on every schedule, nor an aluminum study.

**S2. Honest evidence architecture.** [Institute of Medicine, 2013, The Childhood Immunization Schedule and Safety](https://www.nationalacademies.org/publications/13563); [original report brief](https://nap.nationalacademies.org/resource/13563/ChildhoodImmunizationScheduleandSafety_RB.pdf). The committee did not find evidence of major safety concerns from adherence to the schedule, while identifying research gaps and recommending stronger use of observational systems. An all-vaccines-versus-none randomized trial has ethical and practical problems. Neither “there has never been any schedule research” nor “one report proved every future schedule safe” is defensible.

**S3. Disease risk is not hypothetical, but distinguish undertreatment from any delay.** [Rane et al., JAMA Network Open 2021](https://pubmed.ncbi.nlm.nih.gov/34374773/); [full article](https://pmc.ncbi.nlm.nih.gov/articles/PMC8356064/). Among 316,404 King County children, having fewer age-appropriate DTaP doses was associated with higher pertussis risk. Short delays among otherwise age-appropriately vaccinated children were not associated with increased risk in that study. A precise explainer should preserve this distinction rather than assigning a single risk multiplier to every delayed appointment.

**S4. Measles can impair other immune memory.** [Mina et al., Science 2019](https://pubmed.ncbi.nlm.nih.gov/31672891/), DOI 10.1126/science.aay6485, studied 77 unvaccinated Dutch children before and after measles. Individuals lost 11–73% of their previously detected antibody repertoire; the finding was not seen in the MMR-vaccinated comparison infants and was supported by macaque work. That range refers to measured antibody recognition in this study, not “73% of every child's immune system.” It directly challenges the blanket claim that surviving measles leaves the immune system generally stronger.

**S5. Distinct corroborating mechanism.** [Petrova et al., Science Immunology 2019](https://pubmed.ncbi.nlm.nih.gov/31672862/) describes incomplete reconstruction of B-cell pools after measles. Together with S4 it supports explaining immune amnesia, without claiming every natural infection has the same effects. Disease-acquired immunity can be real and durable; the relevant comparison is the protection obtained along with the risks paid to obtain it.

## 9. Publication guardrails and remaining uncertainties

- **Do not call legitimate uncertainty misinformation.** Allergy, local reactions, age/product contraindications and ethical manufacturing questions deserve accurate answers. A false generalized causal inference is the target, not the fact someone asks about an ingredient.
- **Separate four quantities:** ingredient concentration, total administered dose, internal absorbed/body burden, and risk of the clinical outcome. Comparisons that switch between them are misleading in either direction.
- **Keep local schedules dated.** The U.S. policy environment is changing and subject to litigation; a political directive is not automatically the current implemented clinical schedule. A globally useful page should identify jurisdiction and product version.
- **Do not invent reach.** Article publication, translation, institutional attention, post views and public belief are different observations. No ingredient-specific unique-person exposure measurement was established here. Brand follower totals are not readers of an individual claim.
- **Avoid geographic inflation.** A Spanish-language U.S. article is not a Spanish prevalence study. A multilingual wave proves cross-language recirculation, not independent origin or identical national influence.
- **Avoid science-by-counting.** Many republished articles can derive from one study. A corrected supplement is not a retraction; a preprint is not a clinical recommendation. Mechanistic plausibility is not the same as observed disease causation.
- **Formaldehyde's exact rank remains unresolved.** This search found credible recurrence and strong counterclaim evidence, but no contemporary national formaldehyde-belief question or representative comparison with other ingredient fears. That is a measurement gap, not evidence of zero concern.
- **Best expansion trigger:** promote the formaldehyde section to standalone if the site's own audience questions/search demand, a well-defined independent monitoring dataset, or a large new original dissemination event establishes a distinct need. Repeated copies of one list are insufficient by themselves.

## Recommended content package

1. Ingredient hub: purposes, exact formulations, dose/route/form, formaldehyde, thimerosal, and manufacturing substrates; link specific labels.
2. Aluminum standalone: human evidence, the asthma signal and non-replication, local reactions, route-comparison pitfalls, and the current Danish-study dispute.
3. Schedule/spacing standalone: immune burden versus chemical exposure; what has been studied; uncertainty; susceptible intervals; careful vaccinated/unvaccinated-study appraisal.
4. Natural-immunity explainer, linked to measles and COVID-specific material; compare net outcomes rather than declaring all natural immunity inferior.
5. Existing autism page update: December 2025 WHO review, 2025 Danish cohort, May 2026 systematic review, and links to ingredient explanations. No duplicate autism page.

No site changes, publishing, third-party contact or subscription actions were performed for this research.